First Quarter 2018 Investor Presentation
Investor Presentation
First three months of 2018
Slide 88
Global haemophilia market is growing by high-single digit
Sales of recombinant coagulation factors
RecombinateⓇ/Advate®
NovoSevenⓇ
Coagil VII®
ObizurⓇ1
KogenateⓇ/HelixateⓇ
Strategic positioning of Novo Nordisk's
haemophilia portfolio
Feiba®
XynthaⓇ/RefactoⓇ
Eloctate®
NovoEight®
Idelvion®
RixubisⓇ
Novo Nordisk
compound
Status
Strategic position
AlprolixⓇ
Benefix®
NovoSevenⓇ
Launched
Maintain market leadership
NovoEight®
Launched
Establish presence in a competitive
market place
Submitted³
Contribute to market conversion
40 DKK
billion
35
30
N8-GP
25
CAGR²: 3%
CAGR²: 5%
CAGR²: 9%
20
15
10
5
0
2013
2017
rFVIIa
2013 2017
2013 2017
rFVIII
rFIX
1 ObizurⓇ only indicated for acquired haemophilia
2 CAGR for 5-year period
changing
diabetes®
Refixia®/
RebinynⓇ
Approved 4
Contribute to new treatment paradigm
NovoThirteenⓇ
Launched
Launch first recombinant product
3 Submitted in the USA and the EU in Q1 2018
4 Refixia® is the brand name for N9-GP in the EU, and RebinynⓇ is the brand name in
the US
novo nordiskView entire presentation